Modulation of Prdm9-controlled meiotic chromosome asynapsis overrides hybrid sterility in mice

  1. Sona Gregorova
  2. Vaclav Gergelits  Is a corresponding author
  3. Irena Chvatalova
  4. Tanmoy Bhattacharyya
  5. Barbora Valiskova
  6. Vladana Fotopulosova
  7. Petr Jansa
  8. Diana Wiatrowska
  9. Jiri Forejt  Is a corresponding author
  1. Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Czech Republic

Abstract

Hybrid sterility is one of the reproductive isolation mechanisms leading to speciation. Prdm9, the only known vertebrate hybrid sterility gene, causes failure of meiotic chromosome synapsis and infertility in male hybrids between two mouse subspecies. But within species Prdm9 determines the sites of programmed DNA double-strand breaks and meiotic recombination hotspots. To investigate the relation between Prdm9-controlled meiotic arrest and asynapsis, we inserted random stretches of consubspecific homology on several autosomal pairs in sterile hybrids and analyzed their ability to form synaptonemal complexes and rescue male fertility. Twenty-seven or more Mb of consubspecific (belonging to the same subspecies) homology fully restored synapsis in a given autosomal pair and we predicted that two or more DSBs within symmetric hotspots per chromosome are necessary for successful meiosis. We hypothesize that impaired recombination between evolutionarily diverged chromosomes could function as one of the mechanisms of hybrid sterility occurring in various sexually reproducing species.

Article and author information

Author details

  1. Sona Gregorova

    Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vestec, Czech Republic
    Competing interests
    The authors declare that no competing interests exist.
  2. Vaclav Gergelits

    Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vestec, Czech Republic
    For correspondence
    vaclav.gergelits@img.cas.cz
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5178-8833
  3. Irena Chvatalova

    Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vestec, Czech Republic
    Competing interests
    The authors declare that no competing interests exist.
  4. Tanmoy Bhattacharyya

    Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vestec, Czech Republic
    Competing interests
    The authors declare that no competing interests exist.
  5. Barbora Valiskova

    Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vestec, Czech Republic
    Competing interests
    The authors declare that no competing interests exist.
  6. Vladana Fotopulosova

    Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vestec, Czech Republic
    Competing interests
    The authors declare that no competing interests exist.
  7. Petr Jansa

    Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vestec, Czech Republic
    Competing interests
    The authors declare that no competing interests exist.
  8. Diana Wiatrowska

    Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vestec, Czech Republic
    Competing interests
    The authors declare that no competing interests exist.
  9. Jiri Forejt

    Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Vestec, Czech Republic
    For correspondence
    jforejt@img.cas.cz
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2793-3623

Funding

Czech Science Fundation (13-08078S)

  • Jiri Forejt

Charles University Grant Agency of The Czech Republic (435416)

  • Vaclav Gergelits
  • Barbora Valiskova

Ministry of Education, Youth and Sports of The Czech Republic (LQ1604 project of the NSPII)

  • Jiri Forejt

Charles University Grant Agency of The Czech Republic (17115)

  • Vaclav Gergelits
  • Barbora Valiskova

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The mice were maintained at the Institute of Molecular Genetics in Prague and Vestec, Czech Republic. The project was approved by the Animal Care and use Committee of the Institute of Molecular Genetics AS CR, protocol No 141/2012. The principles of laboratory animal care Czech Act No. 246/1992 Sb., compatible with EU Council Directive 86/609/EEC and Apendix of the Council of Europe Convention ETS, were observed.

Copyright

© 2018, Gregorova et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,385
    views
  • 385
    downloads
  • 58
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sona Gregorova
  2. Vaclav Gergelits
  3. Irena Chvatalova
  4. Tanmoy Bhattacharyya
  5. Barbora Valiskova
  6. Vladana Fotopulosova
  7. Petr Jansa
  8. Diana Wiatrowska
  9. Jiri Forejt
(2018)
Modulation of Prdm9-controlled meiotic chromosome asynapsis overrides hybrid sterility in mice
eLife 7:e34282.
https://doi.org/10.7554/eLife.34282

Share this article

https://doi.org/10.7554/eLife.34282

Further reading

    1. Cell Biology
    2. Chromosomes and Gene Expression
    Bhumil Patel, Maryke Grobler ... Needhi Bhalla
    Research Article

    Meiotic crossover recombination is essential for both accurate chromosome segregation and the generation of new haplotypes for natural selection to act upon. This requirement is known as crossover assurance and is one example of crossover control. While the conserved role of the ATPase, PCH-2, during meiotic prophase has been enigmatic, a universal phenotype when pch-2 or its orthologs are mutated is a change in the number and distribution of meiotic crossovers. Here, we show that PCH-2 controls the number and distribution of crossovers by antagonizing their formation. This antagonism produces different effects at different stages of meiotic prophase: early in meiotic prophase, PCH-2 prevents double-strand breaks from becoming crossover-eligible intermediates, limiting crossover formation at sites of initial double-strand break formation and homolog interactions. Later in meiotic prophase, PCH-2 winnows the number of crossover-eligible intermediates, contributing to the designation of crossovers and ultimately, crossover assurance. We also demonstrate that PCH-2 accomplishes this regulation through the meiotic HORMAD, HIM-3. Our data strongly support a model in which PCH-2’s conserved role is to remodel meiotic HORMADs throughout meiotic prophase to destabilize crossover-eligible precursors and coordinate meiotic recombination with synapsis, ensuring the progressive implementation of meiotic recombination and explaining its function in the pachytene checkpoint and crossover control.

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ashley L Cook, Surojit Sur ... Nicolas Wyhs
    Research Article

    Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.